ClinicalTrials.gg
CompletedNCT06899217Updated Jul 13, 2026

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

A Phase 2 interventional study of CIN-102 Dose 15mg and Placebo in Idiopathic Gastroparesis, sponsored by CinDome Pharma, Inc.. Completed at 85 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
5th of 136
416 · median 36
Started
2025
with 4 others
Phase 2
38 of 184
none open now
Registered
171st of 184
by date
Lead sponsor
4 of 184
CinDome Pharma, Inc.

Among the 184 studies in Gastroparesis with a site in United States, this one is the 5th largest by enrollment of the 136 interventional ones that give a count, is one of 5 that started in 2025, is one of 38 in phase 2, and was the 171st registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.

The main questions it aims to answer are:

  • To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo
  • To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo

Participants will go through the following schedule:

  • Pre-screening (1 visit)
  • Screening \& Lead-In (1-2 visits)

    • Will complete a Gastric Emptying Breath Test (GEBT)
    • Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation.
  • Lead-In Period (1 visit)
  • 12-week treatment period (7 visits)

    • Study drug taken twice daily by mouth
    • Will complete daily diaries and other PROs as described in protocol
  • 1 week follow-up (1 visit)

Researchers will compare the effects of the following treatments:

  • 15 mg CIN-102, taken orally BID for 12 weeks
  • 10 mg CIN-102, taken orally BID for 12 weeks
  • Placebo for CIN-102, taken orally BID for 12 weeks
03

Conditions studied

  • Idiopathic Gastroparesis

Keywords

  • Gastroparesis
  • Idiopathic Gastroparesis
  • Vomiting
  • Early satiety
  • Bloating
  • Epigastric pain
  • Abdominal pain
  • Delayed gastric emptying
  • Dopamine receptor antagonist
  • Nausea
  • Post-prandial fullness
  • Stomach pain
  • Gastric statis
  • Dysmotility
  • Gastric motility
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Is a male or female ≥18 years of age;
  • Has a current diagnosis of gastroparesis defined by the following:

    1. Persistent gastrointestinal (GI) symptoms that, in the opinion of the Investigator, are consistent with gastroparesis within 6 months prior to Screening; and
    2. Documented delayed gastric emptying as determined by gastric emptying breath test (GEBT) at Visit 2.
  • between 17 and 49 kg/m2, inclusive;
  • If receiving treatment with a Food and Drug Administration (FDA)-approved and marketed glucagon-like peptide-1 receptor agonist (GLP-1RA) for weight loss or reduce risk of major adverse cardiovascular events, and/or, receiving any other agent(s) taken for weight loss, subjects may be considered for the study if ALL of the following criteria are satisfied:

    1. Is not taking the agent(s) for the management of diabetes or blood glucose;
    2. Has been on a stable dose of the agent(s) for at least 3 months before Screening and is expected to maintain the same dose throughout the study, including during GEBT;
    3. Is tolerating the agent(s) well, according to the Investigator's judgment;
    4. In the opinion of the Investigator, the study-qualifying signs/symptoms of gastroparesis are NOT solely due to the the agent(s); and
    5. Symptoms of gastroparesis were present before starting the agent(s).

      -------------------------------------------------------------------------

      Key Exclusion Criteria:

  • Has a known primary cause of gastroparesis (eg, diabetes, surgery; acute, ongoing, or active viral illness; cancer, medications, musculoskeletal or connective tissue disorders [eg, scleroderma, systemic lupus erythematosus], or other neurologic disorder [eg, Parkinson's disease], postural orthostatic tachycardia syndrome (POTS), etc.]);
  • Has a current diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association. Pre-diabetes is not exclusionary;
  • Has been hospitalized for gastroparesis or malnutrition within 3 months prior to Screening;
  • Has a known or suspected GI mechanical obstruction (eg, peptic stricture) as documented by upper GI endoscopy, upper GI radiographic series, plain film abdomen X-ray, or computed tomography (CT) in the past 2 years prior to Randomization;
  • Has a history of pyloric injection of botulinum toxin within 6 months of Screening or planned injection(s) during the study;
  • Has any history of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy (G-POEM) procedure;
  • Has a history of gastric surgery;
  • Has a history of or current diagnosis of intestinal malabsorption, recurrent or chronic pancreatitis, or other pancreatic exocrine disease;
  • Has a history of severe and constipation;
  • Has a history or evidence of arrhythmia;
  • Currently receiving parenteral feeding or presence of a nasogastric or other gastric enteral tube (e.g. percutaneous endoscopic gastrostomy [PEG] or percutaneous endoscopic jejunostomy [PEJ] tube) for feeding or decompression; Note: patients receiving enteral feeding via a jejunostomy tube may be included if, in the opinion of the Investigator, the patient is also taking substantial oral solid intake and are not primarily dependent on enteral nutrition
  • Has a substance use disorder or a positive alcohol or positive drug screen.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
416 participants (actual)

Study arms

  • Experimental
    CIN-102: 15mg

    15 mg CIN-102, taken orally BID for 12 weeks

    Drug: CIN-102 Dose 15mg

  • Experimental
    CIN-102: 10mg

    10 mg CIN-102, taken orally BID for 12 weeks

    Drug: CIN-102 Dose 10mg

  • Placebo comparator
    Placebo for CIN-102

    Placebo for CIN-102, taken orally BID for 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.

    The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale Scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe).

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline

Secondary outcomes

  1. The effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline

    Based on the average ANMS GCSI-DD Total Score, Composite of the Nausea and Vomiting Scores, Vomiting Score, Early Satiety Score, Postprandial Fullness Score, upper Abdominal Pain Score, and Vomiting Severity Score

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline

  2. The percentage of subjects who are identified as responders, defined as archiving an average ≥1 point reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, and individual subscale scores

    • The percentage of subjects achieving an average ≥1 point reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period

  3. The percentage of subjects who are identified as responders, defined as archiving an average ≥0.5 point reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, and individual subscale scores

    • The percentage of subjects achieving an average ≥0.5 point reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period

  4. The percentage of subjects who are identified as responders, defined as achieving an average ≥30% reduction from baseline for each of following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores

    • Occurrence of subjects achieving an average ≥ 30% reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period

  5. The percentage of symptom-free days in the ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores.

    A symptom-free day is defined as a day with severity of symptoms assessed as "none" \[ie, ANMS GCSI-DD scores of 0\])

    Time frame: Over the 12-week Treatment Period

  6. The percentage of symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    A symptomatic week is defined as average ANMS GCSI-DD score ≥ 1

    Time frame: Over the 12-week Treatment Period

  7. The percentage of mild, moderate, severe and very severe symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Sponsor to provide definition of each severity score

    Time frame: Over the 12-week Treatment Period

  8. The Patient Global Impression of Change (PGIC) value

    • The absolute change in PGIC over the 12-week Treatment Period

    Time frame: Over the 12-week Treatment Period

  9. The Patient Global Impression of Severity (PGIS) value

    • The absolute change from baseline to Week 12 in PGIS

    Time frame: From baseline to Week 12

  10. The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.

    The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale Scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe).

    Time frame: Over the final 6 weeks of the 12-week Treatment Period as compared to Baseline

  11. The effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline

    Based on the average ANMS GCSI-DD Total Score, Composite of the Nausea and Vomiting Scores, Vomiting Score, Early Satiety Score, Postprandial Fullness Score, upper Abdominal Pain Score, and vomiting severity scores

    Time frame: Over the final 6 weeks of the 12-week Treatment Period as compared to Baseline

  12. The percentage of subjects identified as responders, defined as an average ≥0.5 reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, vomiting severity scores

    • Occurrence of subjects with an average ≥ 0.5 reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Time frame: Over the last 6 weeks of the 12-week Treatment Period

  13. The percentage of subjects identified as responders, defined as achieving ≥30% reduction from baseline for each: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, vomiting severity scores

    • Occurrence of subjects achieving a ≥ 30% reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Time frame: Over the final 6 weeks of the 12-week Treatment Period

  14. The percentage of symptom-free days in the ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    A symptom-free day is defined as a day with severity of symptoms assessed as "none" \[ie, ANMS GCSI-DD scores of 0\])

    Time frame: Over the final 6 weeks of the 12-week Treatment Period

  15. The percentage of symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    A symptomatic week is defined as average ANMS GCSI-DD score ≥ 1

    Time frame: Over the final 6 weeks of the 12-week Treatment Period

  16. The percentage of moderate, severe and very severe symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Sponsor to provide definition of each severity score

    Time frame: Over the final 6 weeks of the 12-week Treatment Period

  17. The Patient Global Impression of Change (PGIC) value

    • The absolute change in PGIC over the 12-week Treatment Period

    Time frame: Over the final 6 weeks of the 12-week Treatment Period

  18. The Patient Global Impression of Severity (PGIS) value

    • The absolute change from baseline to Week 12 in PGIS

    Time frame: Over the final 6 weeks of the 12-week Treatment Period

  19. To assess the safety of CIN-102 compared to placebo in adult subjects with idiopathic gastroparesis from the time of informed consent until the EOS

    * Incidence of clinically significant changes in laboratory parameters, physical examination findings, 12-lead ECG parameters, weight measurements, and vital signs, as assessed by the Investigator * TESAEs * TEAEs leading to premature discontinuation of study drug * Treatment-emergent clinically significant laboratory abnormalities

    Time frame: Over the 12-week Treatment Period

07

Study locations

85 sites
  • Gastro Health - Birmingham
    Birmingham, Alabama 35235, United States
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • The Center for Clinical Trials
    Saraland, Alabama 36571, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85715, United States
  • Applied Research Center of Arkansas, Inc
    Little Rock, Arkansas 72205, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Hope Clinical Research LLC
    Canoga Park, California 91303, United States
  • Erick H. Alayo Medical Corporation
    Chula Vista, California 91910, United States
  • Flourish Research - Los Angeles (Covina)
    Covina, California 91723, United States
  • Gastro Care Institute
    Lancaster, California 93534, United States
  • Downtown L.A. Research Center, Inc.
    Los Angeles, California 90017, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Focus Clinical Research - West Hills
    West Hills, California 91307, United States
  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
  • Rocky Mountain Gastroenterology (RMG)
    Lakewood, Colorado 80228, United States
  • Paradigm Research - Wheatridge
    Wheat Ridge, Colorado 80033, United States
  • Connecticut Clinical Research Institute, LLC
    Bristol, Connecticut 06010, United States
  • American Family Research Group
    Cape Coral, Florida 33909, United States
  • USA and International Research Inc.
    Doral, Florida 33126, United States
  • Unique Clinical Trials
    Doral, Florida 33172, United States
  • Advanced Medical Research Group
    Hollywood, Florida 33021, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • ENCORE Borland Groover Clinical Research
    Jacksonville, Florida 32256, United States
  • Allied Biomedical Research Institute, Inc.
    Miami, Florida 33155, United States
  • Advanced Research Institute Inc
    New Port Richey, Florida 34653, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • GCP Research
    St. Petersburg, Florida 33705, United States
  • Summit Clinical Research, LLC
    Athens, Georgia 30607, United States
  • DelRicht Clinical Research - Atlanta
    Atlanta, Georgia 30329, United States
  • Gastrointestinal Specialists of Georgia PC
    Marietta, Georgia 30060, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • GI Alliance - Gurnee
    Gurnee, Illinois 60031, United States
  • Carle Clinic - Urbana Main
    Urbana, Illinois 61801, United States
  • Integrated Clinical Trial Services, Inc
    West Des Moines, Iowa 50265, United States
  • Kansas Medical Clinic, P.A.
    Topeka, Kansas 66606, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Delta Research Partners of West Monroe, LLC
    Monroe, Louisiana 71201, United States
  • NOLA Research Works
    New Orleans, Louisiana 70125, United States
  • Portland Gastroenterology Associates
    Portland, Maine 04101, United States
  • Capital Digestive Care - Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Sanmora Bespoke: Parkway Medical Association
    Glen Burnie, Maryland 21061, United States
  • Gastro Health - Framingham
    Framingham, Massachusetts 01702, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • Huron Gastroenterology
    Ypsilanti, Michigan 48197, United States
  • Gastrointestinal Associates and Endoscopy Center, PA - Flowood
    Flowood, Mississippi 39232, United States
  • KAD Clinical Research, LLC
    St Louis, Missouri 63123, United States
  • St. Charles Clinical Research
    Weldon Spring, Missouri 63304, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • Digestive Disease Specialists
    Las Vegas, Nevada 89128, United States
  • Advanced Research Institute - Reno
    Reno, Nevada 89511, United States
  • Southwest Gastroenterology Associates
    Albuquerque, New Mexico 87109, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • Westchester Putnam Gastro
    Carmel, New York 10512, United States
  • Atrium Health - Center for Gastroenterology and Hepatology MMP
    Charlotte, North Carolina 28204, United States
  • Cross Creek Medical Clinic, PA
    Fayetteville, North Carolina 28304, United States
  • Carolina Digestive Diseases & Endoscopy Center
    Greenville, North Carolina 27834, United States
  • Peters Medical Research
    High Point, North Carolina 27260, United States
  • Hometown Urgent Care and Research (Cincinnati)
    Cincinnati, Ohio 45150, United States
  • Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health - Columbus
    Columbus, Ohio 43228, United States
  • Hometown Urgent Care and Research - Huber Heights
    Huber Heights, Ohio 45424, United States
  • Gastro Intestinal Research Institute of Northern Ohio, LLC
    Westlake, Ohio 44145, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • Advanced Research Institute - Portland
    Portland, Oregon 97223, United States
  • Susquehanna Research Group, LLC
    Harrisburg, Pennsylvania 17110, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Frontier Clinical Research, LLC - Smithfield
    Smithfield, Pennsylvania 15478, United States
  • PPCP Division of Gastroenterology
    Summerville, South Carolina 29486, United States
  • Galen Medical Group
    Hixson, Tennessee 37343, United States
  • Digestive Health - UT Health Austin
    Austin, Texas 78712, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • EPIC Medical Research
    DeSoto, Texas 75115, United States
  • Amir A Hassan, MD, PA
    Houston, Texas 77089, United States
  • Pioneer Research Solutions Inc.
    Houston, Texas 77099, United States
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
  • North Hills Medical Research Inc. (North Hills Family Medicine)
    North Richland Hills, Texas 76180, United States
  • Bandera Family HealthCare Research, LLC (BFHC)
    San Antonio, Texas 78249, United States
  • GI Alliance - Texas Digestive Disease Consultants - San Marcos
    San Marcos, Texas 78666, United States
  • Texas Digestive Specialists
    Texas City, Texas 78550, United States
  • Advanced Research Institute - Ogden
    Ogden, Utah 84405, United States
  • Advanced Research Institute - Sandy
    Sandy City, Utah 84092, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Capital Digestive Center
    Norfolk, Virginia 23502, United States
  • Advocate Aurora Health Research Institute
    Milwaukee, Wisconsin 53215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2026, 15 months.

Of 20 phase 2 interventional studies under Gastroparesis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Mar 27, 2025
StartActual
Jan 29, 2025
Primary completionActual
May 7, 2026
CompletionActual
May 7, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06899217
Lead sponsor
CinDome Pharma, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Jan 29, 2025
Primary completion
May 7, 2026
Completion
May 7, 2026
Last update
Jul 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CIN-102 · Deudomperidone

Start the discussion